Edwards Lifesciences is in a sustained uptrend, with the stock up 17.0% over the past year and currently trading at 95.8% of its 52-week range ($72.30–$96.29). The price sits near the high end of the range, indicating strong bullish momentum but also potential overextension. The 52-week low of $72.30 was set in early February 2026, and the stock has rallied over 27% from that level, reflecting a decisive recovery and trend reversal. Short-term momentum is accelerating: the 1-month price change is +7.2% and the 3-month change is +18.4%, both outpacing the S&P 500's respective gains of 4.1% and 11.1%. The 1-month relative strength of +3.2% versus the market confirms near-term outperformance. This acceleration aligns with the longer-term uptrend, suggesting strong buying pressure rather than a divergence. The stock's beta of 0.855 indicates it is less volatile than the market, which is unusual for a high-growth medtech name but provides a cushion during pullbacks. Key support lies near the 52-week low of $72.30, while resistance is at the 52-week high of $96.29. A breakout above $96.29 would signal a continuation of the uptrend and open the door to further gains, while a breakdown below $72.30 would negate the recovery and suggest a return to the prior downtrend.

Revenue growth is accelerating: Q4 2025 revenue of $1.57 billion grew 13.3% year-over-year, up from 8.6% growth in Q4 2024 and 5.5% in Q3 2024. The trailing twelve-month revenue reached approximately $6.07 billion. The Transcatheter Heart Valves segment, which generated $1.16 billion in Q4 2025 (74% of total revenue), is the primary growth driver, while Surgical Heart Valve Therapy ($254 million) and Transcatheter Mitral & Tricuspid Therapies ($156 million) contribute smaller but growing portions. The accelerating top-line trend supports the investment case for a company benefiting from demographic tailwinds and product innovation. Profitability remains solid: net income in Q4 2025 was $91.2 million, down sharply from $385.6 million in Q4 2024 due to a one-time charge, but the trailing twelve-month net income was $1.07 billion. Gross margin is consistently high at 78.3% in Q4 2025, reflecting pricing power and manufacturing efficiency. Operating margin was 23.6% in Q4 2025, down from 28.0% in Q3 2025, but still healthy. The company is profitable with a net margin of 17.7% on a TTM basis, though the Q4 2025 net margin compressed to 5.8% due to the charge. The balance sheet is fortress-like: debt-to-equity is just 0.068, and the current ratio is 3.72, indicating ample liquidity. Free cash flow was $353.5 million in Q4 2025 and $1.34 billion on a TTM basis, providing strong internal funding for R&D and potential acquisitions. ROE of 10.4% is respectable for a medtech company, and the company has no dividend, reinvesting all cash into growth.